This guide explains the requirements of the Animal Products Act 1999 in relation to homekill and recreational catch. It also includes key information on animal welfare and recommendations for food safety.

Hormonal growth promotants (HGPs) are a group of veterinary medicines that pose
unique risks to New Zealand’s trade in primary produce. While it is legal to administer
HGPs to beef cattle in New Zealand, certain overseas countries have banned their use.
As New Zealand exports 80% of its beef produce, it became necessary to develop
regulatory controls to ensure HGP-treated beef is not sent to markets that only accept
non-HGP animal products.

An internationally accepted set of guidelines that describe proven systems/procedures for the production of quality for ACVM products.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an antihistamine
product, or to vary the conditions on a registered antihistamine product. It also
incorporates guidelines, which are intended to provide more detailed information and
guidance to applicants to assist them in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an antispasmodic
product, or to vary the conditions on a registered antispasmodic product. It also
incorporates guidelines, which are intended to provide more detailed information and
guidance to applicants to assist them in complying with the standard.

Efficacy of a veterinary medicine is understood to be the degree to which the medicinal
claims made by the applicant have been justified and are likely to be attained under
practical field conditions within New Zealand. The need for an efficacy standard arises
from section 4 of the Agricultural Compounds and Veterinay Medicines (ACVM) Act
1997, which provides for prevention or management of risks associated with the use of
agricultural compounds:
• risks to trade in primary produce; and
• risks to animal welfare; and
• risks to agricultural security.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register a zinc prophylactic
product for facial eczema, or to vary the conditions on a registered zinc prophylactic
product for facial eczema. It also incorporates guidelines, which are intended to provide
more detailed information and guidance to applicants to assist them in complying with
the standard.

While some pain or distress to the animal is inevitable at times from administration of
a product, the intensity and duration must be no more than is necessary to prevent or
treat the condition concerned. Some recognition is therefore required of the extent of
suffering that may arise from the use of alternative products and the suffering that may
arise from not administering the product.

The purpose of the Agricultural Compounds and Veterinary Medicines (ACVM) Act 1997 is to:
(1) manage risks (public health, animal welfare, trade, agricultural security);
(2) ensure that the use of agricultural compounds does not result in breaches of domestic food residue standards;
(3) ensure the provision of sufficient consumer information about agricultural compounds.
Conditions are placed on product registrations to help achieve this purpose.

This document has been prepared by the Meat Industry Association (MIA) in partnership with MPI. It provides guidance to the meat industry on how to meet the requirements of the Animal Products (Risk Organism Response Plans) Notice 2008.

General requirements for completion of MPI application forms

This guidance document is to provide information on the process of becoming an MPI-listed data assessor to carry out independent data assessment in specified areas and to prepare data assessment reports concerning trade name products for registration (or variation) applications under the ACVM Act.

The MPI Bee Pathogen Programme is funded by MPI’s Operational Research and Department funds through the Diagnostic and Surveillance Directorate. The programme is investigating the prevalence and incidence of bee pathogens in New Zealand, using new methods developed by MPI that are based on the National Apiculture Surveys in the USA and Canada.

This guidance document has been issued to accompany Bovine Semen to the United States of America (OMAR). This guidance document should be read in conjunction with that OMAR.

This guidance document supports the recently introduced Prevalence Performance Target for Campylobacter that was introduced by the Animal Products (National Microbiological Database Specifications) Amendment Notice 2016 and came into effect on 3 April 2016. The guidance document is intended to assist poultry operators to review their slaughter and dressing procedures and the operation of specific control measures for Campylobacter when first setting up their process and reviewing when issues arise.